PML and myeloid sarcoma: In addition, as suggested for PML reactivation in natalizumab treated MS patients [46], [47], the blockade of a4 integrin could affect normal bone marrow physiology resulting in release of premature lymphoid progenitor harboring latent virus(es) into the circulation.